Metabolic Brain Disease 2007-03-01

Hepatic encephalopathy following transjugular intrahepatic portosystemic shunt (TIPS): management with L-ornithine-L-aspartate and stent reduction.

Vanessa Stadlbauer, Josef Tauss, Horst R Portugaller, Philipp Stiegler, Florian Iberer, Rudolf E Stauber

Index: Metab. Brain Dis. 22(1) , 45-50, (2007)

Full Text: HTML

Abstract

Hepatic encephalopathy (HE) is a common problem after insertion of a trans-jugular intrahepatic portosystemic shunt (TIPS), which may be difficult to manage. We present a case of severe post-TIPS HE unresponsive to high doses of L-ornithine-L-aspartate (LOLA) despite reduction of venous ammonia levels in a dose-dependent fashion. Ultimately, high-grade HE was successfully treated by a reduction stent and the patient subsequently underwent successful liver transplantation.

Related Compounds

  • L-Ornithine L-asp...

Related Articles:

Modulation of neural activation following treatment of hepatic encephalopathy.

2013-03-12

[Neurology 80(11) , 1041-7, (2013)]

L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis.

2009-01-01

[J. Gastroenterol. Hepatol. 24(1) , 9-14, (2009)]

A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis.

2010-04-01

[Liver Int. 30(4) , 574-82, (2010)]

The treatment of hepatic encephalopathy.

2007-12-01

[Metab. Brain Dis. 22(3-4) , 389-405, (2007)]

Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS.

2014-07-01

[Aliment. Pharmacol. Ther. 40(1) , 63-71, (2014)]

More Articles...